News & Updates

Show Multimedia Only
Biomarker-driven therapies superior to standard care in breast cancer

Biomarker-driven therapies superior to standard care in breast cancer

02 Nov 2023

Patients with breast cancer may gain greater therapeutic advantages from biomarker-driven than standard-of-care therapies, suggests a study.

02 Nov 2023
First-line therapies for advanced NSCLC improve survival, QoL

First-line therapies for advanced NSCLC improve survival, QoL

16 Oct 2023

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

16 Oct 2023